Status:
WITHDRAWN
Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Hepatocellular Carcinoma
Hepatocellular Cancer
Eligibility:
All Genders
1-99 years
Brief Summary
Background: Fibrolamellar Hepatocellular Carcinoma (FL-HCC) is a rare liver cancer. It usually occurs in young people who have no history of liver disease. Currently the only effective treatment opti...
Detailed Description
Background: * Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare hepatocellular carcinoma accounting for 0.5-9% of primary liver cancer in various case series, which is usually not associated ...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Subjects enrolled on NCI protocol Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors
- Subjects of all ages with histologically or cytologically proven FL-HCC.
- Ability of subject to understand and the willingness to sign a written informed consent document.
- EXCLUSION CRITERIA:
- None
Exclusion
Key Trial Info
Start Date :
April 8 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 23 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03748927
Start Date
April 8 2019
End Date
March 23 2020
Last Update
March 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892